Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation due to allegations of violations of federal securities laws and poor performance on safety measures in their hospitals [1][3]. Group 1: Allegations and Investigations - A New York Times article reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of preventable readmissions [3]. - The investigation by Bragar Eagel & Squire focuses on whether Encompass has engaged in unlawful business practices related to these allegations [1][3]. Group 2: Stock Market Impact - Following the publication of the allegations, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share on July 15, 2025, resulting in financial harm to investors [4]. Group 3: Legal Support for Investors - Investors who purchased Encompass shares and suffered losses are encouraged to contact Bragar Eagel & Squire for potential legal recourse [5].